• Peer-reviewed JAHA publication strengthens the foundation for Cardiol’s pivotal Phase III MAVERIC trial as enrollment nears completion.TORONTO, July 14, 2026 /PRNewswire/ — Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (“Cardiol” or the “Company”), a late-stage life sciences company…





